Drugs / VEE TC-83
VEE TC-83
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00582504 | Sep 2007 → Dec 2021 | Venezuelan equine encephalitis | U.S. Army Medical Research and Development Command | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VEE TC-83 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00582504 ↗ |
| Known as | NDBR-102 | “This study is designed to determine safety of and immune response to Venezuelan Equine Encephalomyelitis Vaccine, Live, Attenuated, Dried TC-83, NDBR-102 (TC-83).” NCT00582504 ↗ |
| Known as | TC-83 | “This study is designed to determine safety of and immune response to Venezuelan Equine Encephalomyelitis Vaccine, Live, Attenuated, Dried TC-83, NDBR-102 (TC-83).” NCT00582504 ↗ |
| Known as | Venezuelan Equine Encephalomyelitis Vaccine, Live, Attenuated, Dried | “This study is designed to determine safety of and immune response to Venezuelan Equine Encephalomyelitis Vaccine, Live, Attenuated, Dried TC-83, NDBR-102 (TC-83).” NCT00582504 ↗ |
| Modality | Vaccine | “Venezuelan Equine Encephalomyelitis Vaccine” NCT00582504 ↗ |
| Route | Subcutaneous | “by subcutaneous route” NCT00582504 ↗ |